OBG SCIENTIFIC DIVISION LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
Company Registration No. 09987650 (England and Wales)
OBG SCIENTIFIC DIVISION LIMITED
COMPANY INFORMATION
Directors
Mr P Didlick
Mr P M O'Brien
Mr G F O'Brien
Company number
09987650
Registered office
Ayrton House
Commerce Way
Liverpool
L8 7BA
Auditor
DSG Audit
Castle Chambers
43 Castle Street
Liverpool
L2 9TL
OBG SCIENTIFIC DIVISION LIMITED
CONTENTS
Page
Strategic report
1
Directors' report
2
Directors' responsibilities statement
3
Independent auditor's report
4 - 6
Profit and loss account
7
Statement of comprehensive income
8
Balance sheet
9
Statement of changes in equity
10
Notes to the financial statements
11 - 16
OBG SCIENTIFIC DIVISION LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -

The directors present the strategic report for the year ended 31 December 2024.

Principal activity and fair review of business

The principal activity of the company continued to be that of a holding company.

 

The results for the year are shown in the attached financial statements.

 

The company has net assets of £6 (2023: net liabilities of £259,995).

 

As the company is a holding company there are no other measures that are considered to be key performance indicators.

Principal risks and uncertainties

The principal risks and uncertainties facing the company, other than disclosed below, relate to the business risks faced by its subsidiaries.

 

Liquidity risk

The company is funded by surplus cash, bank borrowings and working capital, together with intra-group financing arrangements.

 

The company manages its cash and borrowing requirements in order to maximise interest income and minimise interest expense, whilst ensuring the company has sufficient liquid resources to meet the operating needs of the business.

 

Credit risk

The company monitors credit risk closely and considers that its current policies of credit checks meets its objectives. All customers who wish to trade on credit terms are subject to credit verification procedures.

On behalf of the board

Mr P Didlick
Director
13 August 2025
OBG SCIENTIFIC DIVISION LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -

The directors present their annual report and financial statements for the year ended 31 December 2024.

Results and dividends

The results for the year are set out on page 7.

Ordinary dividends were paid amounting to £190,000. The directors do not recommend payment of a final dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mr P Didlick
Mr P M O'Brien
Mr G F O'Brien
Mr M Bromiley
(Resigned 7 March 2025)
Auditor

The auditor, DSG Audit, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

Strategic report

The company has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the company's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report. It has done so in respect of the company's principal activity and financial risk management policies.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

Medium-sized companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the medium-sized companies exemption.

On behalf of the board
Mr P Didlick
Director
13 August 2025
OBG SCIENTIFIC DIVISION LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

OBG SCIENTIFIC DIVISION LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF OBG SCIENTIFIC DIVISION LIMITED
- 4 -
Opinion

We have audited the financial statements of OBG Scientific Division Limited (the 'company') for the year ended 31 December 2024 which comprise the profit and loss account, the statement of comprehensive income, the balance sheet, the statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

OBG SCIENTIFIC DIVISION LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF OBG SCIENTIFIC DIVISION LIMITED (CONTINUED)
- 5 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report and the directors' report.

 

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Discussions were held with, and enquiries made of, management and those charged with governance with a view to identifying those laws and regulations that could be expected to have a material impact on the financial statements. During the engagement team briefing, the outcomes of these discussions and enquiries were shared with the team, as well as consideration as to where and how fraud may occur in the company. 

The following laws and regulations were identified as being of significance to the company:

Audit procedures undertaken in response to the potential risks relating to irregularities (which include fraud and non-compliance with laws and regulations) comprised of: enquiries of management and those charged with governance as to whether the company complies with such laws and regulations; enquiries with the same concerning any actual or potential litigation or claims; inspection of relevant legal correspondence; testing the appropriateness of entries in the nominal ledger, including journal entries; reviewing transactions around the end of the reporting period; and the performance of analytical procedures to identify unexpected movements in account balances which may be indicative of fraud.

OBG SCIENTIFIC DIVISION LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF OBG SCIENTIFIC DIVISION LIMITED (CONTINUED)
- 6 -

No instances of material non-compliance were identified. However, the likelihood of detecting irregularities, including fraud, is limited by the inherent difficulty in detecting irregularities, the effectiveness of the company’s controls, and the nature, timing and extent of the audit procedures performed. Irregularities that result from fraud might be inherently more difficult to detect than irregularities that result from error.  As explained above, there is an unavoidable risk that material misstatements may not be detected, even though the audit has been planned and performed in accordance with ISAs (UK).

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Laura Leslie BSc FCA (Senior Statutory Auditor)
For and on behalf of DSG Audit, Statutory Auditor
Chartered Accountants
Castle Chambers
43 Castle Street
Liverpool
L2 9TL
13 August 2025
OBG SCIENTIFIC DIVISION LIMITED
PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
2024
2023
Notes
£
£
Administrative expenses
-
0
(1)
Exceptional item
2
-
0
(300,000)
Operating profit/(loss)
-
(300,001)
Interest receivable and similar income
4
450,001
-
0
Profit/(loss) before taxation
450,001
(300,001)
Tax on profit/(loss)
6
-
0
-
0
Profit/(loss) for the financial year
450,001
(300,001)
OBG SCIENTIFIC DIVISION LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
2024
2023
£
£
Profit/(loss) for the year
450,001
(300,001)
Other comprehensive income
-
-
Total comprehensive income for the year
450,001
(300,001)
OBG SCIENTIFIC DIVISION LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 9 -
2024
2023
Notes
£
£
£
£
Fixed assets
Investments
7
1,008
1,008
Current assets
Debtors
9
260,001
-
0
Cash at bank and in hand
6
6
260,007
6
Creditors: amounts falling due within one year
10
(261,009)
(261,009)
Net current liabilities
(1,002)
(261,003)
Net assets/(liabilities)
6
(259,995)
Capital and reserves
Called up share capital
11
6
6
Profit and loss reserves
-
0
(260,001)
Total equity
6
(259,995)

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 13 August 2025 and are signed on its behalf by:
Mr P Didlick
Director
Company registration number 09987650 (England and Wales)
OBG SCIENTIFIC DIVISION LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 January 2023
6
40,000
40,006
Year ended 31 December 2023:
Loss and total comprehensive income
-
(300,001)
(300,001)
Balance at 31 December 2023
6
(260,001)
(259,995)
Year ended 31 December 2024:
Profit and total comprehensive income
-
450,001
450,001
Dividends
5
-
(190,000)
(190,000)
Balance at 31 December 2024
6
-
0
6
OBG SCIENTIFIC DIVISION LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 11 -
1
Accounting policies
Company information

OBG Scientific Division Limited is a private company limited by shares incorporated in England and Wales. The registered office is Ayrton House, Commerce Way, Liverpool, L8 7BA.

 

The principal activity of the company is disclosed in the strategic report.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

The financial statements of the company are consolidated in the financial statements of OBG Holding Limited. These consolidated financial statements are available from its registered office at Ayrton House, 38 Commerce Way, Parliament Business Park, Liverpool, L8 7BA.

The company has taken advantage of the exemption under section 400 of the Companies Act 2006 not to prepare consolidated accounts. The financial statements present information about the company as an individual entity and not about its group.

 

OBG Scientific Division Limited is a subsidiary of the ultimate parent company OBG Holding Limited and the results of OBG Scientific Division Limited are included in the consolidated financial statements of OBG Holding Limited, which are available from the address above.

1.2
Going concern

The company has net current liabilities of £1,002 (2023: £261,003) and net assets of £6 (2023: net liabilities of £259,995) and is dependent on the continued support of its fellow group companies in order to meet its financial obligations as and when they fall due. true

 

The group prepares forecasts, which includes this company, which indicate that the company and the group will continue to generate cash, over the period considered by them in their assessment of the appropriateness of adopting the going concern basis in the preparation of these financial statements. The forecasts also demonstrate that existing group banking facilities will remain adequate and that all associated banking covenants will be satisfactorily met. Having made appropriate enquiries the directors consider it appropriate to prepare these financial statements on a going concern basis.

OBG SCIENTIFIC DIVISION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 12 -
1.3
Fixed asset investments

Interests in subsidiaries are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.4
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

OBG SCIENTIFIC DIVISION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 13 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7

Exceptional items

Exceptional items are disclosed separately in the financial statements where it is necessary to do so to provide further understanding of the financial performance of the company. They are material items of income or expenditure which are of exceptional size or incidence, and are presented within the line items to which they best relate.

2
Exceptional item
2024
2023
£
£
Expenditure
Exceptional item
-
300,000

There were no exceptional items in the current year. Exceptional items in the prior year related to the write off of intercompany balances.

OBG SCIENTIFIC DIVISION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 14 -
3
Employees

The average monthly number of persons employed by the company during the year was:

2024
2023
Number
Number
Total
0
0
4
Interest receivable and similar income
2024
2023
£
£
Income from fixed asset investments
Income from shares in group undertakings
450,001
-
0
5
Dividends
2024
2023
£
£
Interim paid
190,000
-
0
6
Taxation

The actual charge for the year can be reconciled to the expected charge/(credit) for the year based on the profit or loss and the standard rate of tax as follows:

2024
2023
£
£
Profit/(loss) before taxation
450,001
(300,001)
Expected tax charge/(credit) based on the standard rate of corporation tax in the UK of 25.00% (2023: 23.52%)
112,500
(70,560)
Tax effect of expenses that are not deductible in determining taxable profit
-
0
70,560
Dividend income
(112,500)
-
0
Taxation charge for the year
-
-

 

OBG SCIENTIFIC DIVISION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 15 -
7
Fixed asset investments
2024
2023
Notes
£
£
Investments in subsidiaries
8
1,008
1,008
8
Subsidiaries

Details of the company's subsidiaries at 31 December 2024 are as follows:

Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
Ayrton Saunders Limited
Ayrton House, L8 7BA
Holder of intellectual property
Ordinary shares
100.00
J M Loveridge Limited
Ayrton House, L8 7BA
Non-trading
Ordinary shares
100.00
Pharmaserve (North West) Development Company Limited
Ayrton House, L8 7BA
Development of specialist pharmaceutical products
Ordinary shares
100.00
Pharmaserve (North West) Limited
Ayrton House, L8 7BA
In administration
Ordinary shares
100.00
Ayrton Saunders (Development) Ltd
Progress House, L8 7BA
Development and commercialisation of inhalation products
Ordinary shares
100.00
Ayrton Saunders Inhalation Ltd
Progress House, L8 7BA
Development and commercialisation of inhalation products
Ordinary shares
100.00
Ayrton Saunders (Ireland) Ltd
Sandyford Business Centre, Dublin, Ireland
Dormant
Ordinary shares
100.00
Ayrton Saunders, Inc.
Delaware, USA
Dissolved during the year
Ordinary shares
100.00
OBG Consumer Reg Scientific Ltd
Progress House, L8 7BA
Development and manufacture of respiratory medicines
Ordinary shares
100.00
OBG Consumer Scientifc Ltd
Progress House, L8 7BA
Development and manufacture of respiratory medicines
Ordinary shares
100.00
Nicovations New Zealand Ltd
Auckland, New Zealand
Dormant
Ordinary shares
100.00

 

9
Debtors
2024
2023
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
260,001
-
0

Amounts owed by group undertakings are unsecured, interest free, and repayable on demand.

OBG SCIENTIFIC DIVISION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 16 -
10
Creditors: amounts falling due within one year
2024
2023
£
£
Amounts owed to group undertakings
261,009
261,009

Amounts owed to group undertakings are unsecured, interest free, and payable on demand.

11
Share capital
2024
2023
£
£
Ordinary share capital
Issued and fully paid
6,204,979 (2023: 6,204,979) Ordinary shares of 0.000001p each
6
6
201,814 (2023: 201,814) Ordinary C shares of 0.000001p each
-
0
-
0

The holders of ordinary shares are entitled to one vote and have a right to receive dividends, pro-rata according to number of shares held. The shares are not redeemable.

 

The holders of the ordinary C shares are not entitled to vote but do have a right to receive to dividends, pro-rata according to number of shares held. The shares are not redeemable.

12
Related party transactions

There were no transactions during the year with related parties other than with group companies. The company is exempt from disclosing transactions with group companies that are wholly owned within the same group.

 

The company owes £260,000 (2023: £260,000) to fellow group undertakings, who are not 100% owned but have common shareholders and directors.

13
Ultimate controlling party

The company is a wholly owned subsidiary of OBG Pharmaceuticals Limited which itself is a wholly owned subsidiary of the ultimate parent company, OBG Holding Limited. The ultimate parent company which prepares consolidated financial statements, is registered in England and Wales at Ayrton House, 38 Commerce Way, Parliament Business Park, Liverpool, L8 7BA. The parent company also has the same registered office as the ultimate parent company.

 

The smallest and largest group into which the results of this entity are consolidated is that headed by OBG Holding Limited.

 

The ultimate controlling party as at the year end 31 December 2024 and up to 31 March 2025 was Mr G F O'Brien. The ultimate controlling party from 1 April 2025 is Mr P M O'Brien.

2024-12-312024-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr P DidlickMr P M O'BrienMr G F O'BrienMr M Bromiley099876502024-01-012024-12-3109987650bus:Director12024-01-012024-12-3109987650bus:Director22024-01-012024-12-3109987650bus:Director32024-01-012024-12-3109987650bus:Director42024-01-012024-12-3109987650bus:RegisteredOffice2024-01-012024-12-31099876502024-12-31099876502023-01-012023-12-3109987650core:ContinuingOperationscore:Exceptional12024-01-012024-12-3109987650core:Exceptional12023-01-012023-12-3109987650core:RetainedEarningsAccumulatedLosses2023-01-012023-12-3109987650core:RetainedEarningsAccumulatedLosses2024-01-012024-12-31099876502023-12-3109987650core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3109987650core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3109987650core:ShareCapital2024-12-3109987650core:ShareCapital2023-12-3109987650core:RetainedEarningsAccumulatedLosses2024-12-3109987650core:RetainedEarningsAccumulatedLosses2023-12-3109987650core:ShareCapital2022-12-3109987650core:RetainedEarningsAccumulatedLosses2022-12-3109987650core:ShareCapitalOrdinaryShareClass12024-12-3109987650core:ShareCapitalOrdinaryShareClass12023-12-3109987650core:ShareCapitalOrdinaryShareClass42024-12-3109987650core:ShareCapitalOrdinaryShareClass42023-12-3109987650core:UKTax2024-01-012024-12-3109987650core:UKTax2023-01-012023-12-3109987650core:Non-currentFinancialInstruments2024-12-3109987650core:Non-currentFinancialInstruments2023-12-3109987650core:Subsidiary12024-01-012024-12-3109987650core:Subsidiary22024-01-012024-12-3109987650core:Subsidiary32024-01-012024-12-3109987650core:Subsidiary42024-01-012024-12-3109987650core:Subsidiary52024-01-012024-12-3109987650core:Subsidiary62024-01-012024-12-3109987650core:Subsidiary72024-01-012024-12-3109987650core:Subsidiary82024-01-012024-12-3109987650core:Subsidiary92024-01-012024-12-3109987650core:Subsidiary102024-01-012024-12-3109987650core:Subsidiary112024-01-012024-12-3109987650core:Subsidiary112024-01-012024-12-3109987650core:Subsidiary222024-01-012024-12-3109987650core:Subsidiary332024-01-012024-12-3109987650core:Subsidiary442024-01-012024-12-3109987650core:Subsidiary552024-01-012024-12-3109987650core:Subsidiary662024-01-012024-12-3109987650core:Subsidiary772024-01-012024-12-3109987650core:Subsidiary882024-01-012024-12-3109987650core:Subsidiary992024-01-012024-12-3109987650core:Subsidiary10102024-01-012024-12-3109987650core:Subsidiary11112024-01-012024-12-3109987650core:CurrentFinancialInstruments2024-12-3109987650core:CurrentFinancialInstruments2023-12-3109987650bus:PrivateLimitedCompanyLtd2024-01-012024-12-3109987650bus:FRS1022024-01-012024-12-3109987650bus:Audited2024-01-012024-12-3109987650bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP